Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Deep sequencing reveals distinct microRNA-mRNA signatures that differentiate pancreatic neuroendocrine tumor from non-diseased pancreas tissue

N. Matyasovska, N. Valkova, M. Gala, S. Bendikova, A. Abdulhamed, V. Palicka, N. Renwick, P. Čekan, E. Paul

. 2025 ; 25 (1) : 669. [pub] 20250411

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25016120

Grantová podpora
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
2019/69 MXDX-1 Ministry of Health of the Slovak Republic
UHHK, 00179906 Ministry of Health Czech Republic
UHHK, 00179906 Ministry of Health Czech Republic
SVV UK, LFHK, No. 260657 Charles University, project GA UK
SVV UK, LFHK, No. 260657 Charles University, project GA UK

BACKGROUND: Only a limited number of biomarkers guide personalized management of pancreatic neuroendocrine tumors (PanNETs). Transcriptome profiling of microRNA (miRs) and mRNA has shown value in segregating PanNETs and identifying patients more likely to respond to treatment. Because miRs are key regulators of mRNA expression, we sought to integrate expression data from both RNA species into miR-mRNA interaction networks to advance our understanding of PanNET biology. METHODS: We used deep miR/mRNA sequencing on six low-grade/high-risk, well-differentiated PanNETs compared with seven non-diseased tissues to identify differentially expressed miRs/mRNAs. Then we crossed a list of differentially expressed mRNAs with a list of in silico predicted mRNA targets of the most and least abundant miRs to generate high probability miR-mRNA interaction networks. RESULTS: Gene ontology and pathway analyses revealed several miR-mRNA pairs implicated in cellular processes and pathways suggesting perturbed neuroendocrine function (miR-7 and Reg family genes), cell adhesion (miR-216 family and NLGN1, NCAM1, and CNTN1; miR-670 and the claudins, CLDN1 and CLDN2), and metabolic processes (miR-670 and BCAT1/MPST; miR-129 and CTH). CONCLUSION: These novel miR-mRNA interaction networks identified dysregulated pathways not observed when assessing mRNA alone and provide a foundation for further investigation of their utility as diagnostic and predictive biomarkers.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016120
003      
CZ-PrNML
005      
20250731091530.0
007      
ta
008      
250708s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12885-025-14043-w $2 doi
035    __
$a (PubMed)40217502
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Matyasovska, N $u MultiplexDX, s.r.o, Comenius University Science Park, Bratislava, Slovakia $u MultiplexDX, Inc, Rockville, MD, USA $u Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
245    10
$a Deep sequencing reveals distinct microRNA-mRNA signatures that differentiate pancreatic neuroendocrine tumor from non-diseased pancreas tissue / $c N. Matyasovska, N. Valkova, M. Gala, S. Bendikova, A. Abdulhamed, V. Palicka, N. Renwick, P. Čekan, E. Paul
520    9_
$a BACKGROUND: Only a limited number of biomarkers guide personalized management of pancreatic neuroendocrine tumors (PanNETs). Transcriptome profiling of microRNA (miRs) and mRNA has shown value in segregating PanNETs and identifying patients more likely to respond to treatment. Because miRs are key regulators of mRNA expression, we sought to integrate expression data from both RNA species into miR-mRNA interaction networks to advance our understanding of PanNET biology. METHODS: We used deep miR/mRNA sequencing on six low-grade/high-risk, well-differentiated PanNETs compared with seven non-diseased tissues to identify differentially expressed miRs/mRNAs. Then we crossed a list of differentially expressed mRNAs with a list of in silico predicted mRNA targets of the most and least abundant miRs to generate high probability miR-mRNA interaction networks. RESULTS: Gene ontology and pathway analyses revealed several miR-mRNA pairs implicated in cellular processes and pathways suggesting perturbed neuroendocrine function (miR-7 and Reg family genes), cell adhesion (miR-216 family and NLGN1, NCAM1, and CNTN1; miR-670 and the claudins, CLDN1 and CLDN2), and metabolic processes (miR-670 and BCAT1/MPST; miR-129 and CTH). CONCLUSION: These novel miR-mRNA interaction networks identified dysregulated pathways not observed when assessing mRNA alone and provide a foundation for further investigation of their utility as diagnostic and predictive biomarkers.
650    _2
$a lidé $7 D006801
650    12
$a nádory slinivky břišní $x genetika $x patologie $x diagnóza $7 D010190
650    12
$a mikro RNA $x genetika $7 D035683
650    12
$a neuroendokrinní nádory $x genetika $x patologie $x diagnóza $7 D018358
650    12
$a messenger RNA $x genetika $7 D012333
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a vysoce účinné nukleotidové sekvenování $x metody $7 D059014
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a genové regulační sítě $7 D053263
650    _2
$a ženské pohlaví $7 D005260
650    12
$a pankreas $x metabolismus $x patologie $7 D010179
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
700    1_
$a Valkova, N $u MultiplexDX, s.r.o, Comenius University Science Park, Bratislava, Slovakia $u MultiplexDX, Inc, Rockville, MD, USA
700    1_
$a Gala, M $u MultiplexDX, s.r.o, Comenius University Science Park, Bratislava, Slovakia $u MultiplexDX, Inc, Rockville, MD, USA
700    1_
$a Bendikova, S $u MultiplexDX, s.r.o, Comenius University Science Park, Bratislava, Slovakia $u MultiplexDX, Inc, Rockville, MD, USA
700    1_
$a Abdulhamed, A $u Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada
700    1_
$a Palicka, V $u Institute of Clinical Biochemistry and Diagnostics, Faculty of Medicine in Hradec Kralove, University Hospital, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Renwick, Neil $u Laboratory of Translational RNA Biology, Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada. neil.renwick@queensu.ca $u Laboratory of RNA Molecular Biology, The Rockefeller University, New York, NY, USA. neil.renwick@queensu.ca
700    1_
$a Čekan, Pavol $u MultiplexDX, s.r.o, Comenius University Science Park, Bratislava, Slovakia. pavol@multiplexdx.com $u MultiplexDX, Inc, Rockville, MD, USA. pavol@multiplexdx.com
700    1_
$a Paul, Evan $u MultiplexDX, s.r.o, Comenius University Science Park, Bratislava, Slovakia. paul@multiplexdx.com $u MultiplexDX, Inc, Rockville, MD, USA. paul@multiplexdx.com
773    0_
$w MED00008171 $t BMC cancer $x 1471-2407 $g Roč. 25, č. 1 (2025), s. 669
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40217502 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091524 $b ABA008
999    __
$a ok $b bmc $g 2366748 $s 1253245
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 25 $c 1 $d 669 $e 20250411 $i 1471-2407 $m BMC cancer $n BMC Cancer $x MED00008171
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a 2019/69 MXDX-1 $p Ministry of Health of the Slovak Republic
GRA    __
$a UHHK, 00179906 $p Ministry of Health Czech Republic
GRA    __
$a UHHK, 00179906 $p Ministry of Health Czech Republic
GRA    __
$a SVV UK, LFHK, No. 260657 $p Charles University, project GA UK
GRA    __
$a SVV UK, LFHK, No. 260657 $p Charles University, project GA UK
LZP    __
$a Pubmed-20250708

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...